{"denoms":[{"counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"117"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"18"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"29"},{"groupId":"BG011","value":"6"},{"groupId":"BG012","value":"6"},{"groupId":"BG013","value":"6"},{"groupId":"BG014","value":"6"},{"groupId":"BG015","value":"6"},{"groupId":"BG016","value":"14"},{"groupId":"BG017","value":"34"},{"groupId":"BG018","value":"5"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"57"},{"groupId":"BG021","value":"5"},{"groupId":"BG022","value":"5"},{"groupId":"BG023","value":"353"}],"units":"Participants"}],"groups":[{"description":"Participants received 0.08 or 0.1 mg of Pegilodecakin once daily (QD) administered subcutaneously (SC).\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG000","title":"Part A: Pegilodecakin 0.08/0.1 mg"},{"description":"Participants received 0.2 or 0.25 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG001","title":"Part A: Pegilodecakin 0.2/0.25 mg"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG002","title":"Part A: Pegilodecakin 0.4/0.5 mg"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG003","title":"Part A: Pegilodecakin 0.8/1 mg"},{"description":"Participants received 1.6 or 2 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG004","title":"Part A: Pegilodecakin 1.6/2 mg"},{"description":"Participants received 3.2 or 4 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial","id":"BG005","title":"Part A: Pegilodecakin 3.2/4 mg"},{"description":"Participants received 0.2 or 0.25 mg of Pegilodecakin QD administered SC along with Platinum/Taxane combination on Day 1 of each 21-day cycle for a maximum of 5 or 6 cycles. Participants received:\n\nPaclitaxel 200 or 175 mg/m² intravenously (IV) over 3 hours, or docetaxel 75 or 65 mg/m² IV over 1 hour, followed by carboplatin (AUC 6/5/4; max 6 × 150 mg) IV over 30 minutes or cisplatin 75 mg/m² IV over 6-8 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG006","title":"Part B: Pegilodecakin 0.2/0.25 mg + Platinum/Taxane"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC along with Platinum/Taxane combination on Day 1 of each 21-day cycle for a maximum of 5 or 6 cycles. Participants received:\n\nPaclitaxel 200 or 175 mg/m² intravenously (IV) over 3 hours, or docetaxel 75 or 65 mg/m² IV over 1 hour, followed by carboplatin (AUC 6/5/4; max 6 × 150 mg) IV over 30 minutes or cisplatin 75 mg/m² IV over 6-8 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG007","title":"Part B: Pegilodecakin 0.4/0.5 mg + Platinum/Taxane"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC along with Platinum/Taxane combination on Day 1 of each 21-day cycle for a maximum of 5 or 6 cycles. Participants received:\n\nPaclitaxel 200 or 175 mg/m² intravenously (IV) over 3 hours, or docetaxel 75 or 65 mg/m² IV over 1 hour, followed by carboplatin (AUC 6/5/4; max 6 × 150 mg) IV over 30 minutes or cisplatin 75 mg/m² IV over 6-8 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG008","title":"Part B: Pegilodecakin 0.8/1 mg + Platinum/Taxane"},{"description":"Participants received 0.2 or 0.25 mg of Pegilodecakin QD administered SC and FOLFOX treatment on Day 1 of each 14-day cycle for a maximum of 12 cycles. Participants received:\n\noxaliplatin 85 mg/m2 IV over 2 hours, and leucovorin 200 mg/m2 IV over 2 hours, followed by 5-Fluorouracil (FU) 400 mg/m2 IV bolus over 2-4 minutes, 5-FU 600 mg/m2/day IV over 22 hours, and leucovorin 200 mg/m2 over 2 hours on Day 2 followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, and 5-FU 600 mg/m2/day IV over 22 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG009","title":"Part C: Pegilodecakin 0.2/0.25 mg + FOLFOX"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC and FOLFOX treatment on Day 1 of each 14-day cycle for a maximum of 12 cycles. Participants received:\n\noxaliplatin 85 mg/m2 IV over 2 hours, and leucovorin 200 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, 5-FU 600 mg/m2/day IV over 22 hours, and leucovorin 200 mg/m2 over 2 hours on Day 2 followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, and 5-FU 600 mg/m2/day IV over 22 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG010","title":"Part C: Pegilodecakin 0.4/0.5 mg + FOLFOX"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC and FOLFOX treatment on Day 1 of each 14-day cycle for a maximum of 12 cycles. Participants received:\n\noxaliplatin 85 mg/m2 IV over 2 hours, and leucovorin 200 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, 5-FU 600 mg/m2/day IV over 22 hours, and leucovorin 200 mg/m2 over 2 hours on Day 2 followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, and 5-FU 600 mg/m2/day IV over 22 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG011","title":"Part C: Pegilodecakin 0.8/1 mg + FOLFOX"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC with Gemcitabine 1000 mg/m² IV over 30 minutes plus nab-paclitaxel 125 mg/m² IV over 30 to 40 minutes on Days 1, 8, and 15 of every 28-day cycle. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG012","title":"Part D: Pegilodecakin 0.4/ 0.5 mg + Gemcitabine/Nab-Paclitaxel"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with Capecitabine 1000 mg/m² orally twice daily (BID) on Days 1 through 14 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG013","title":"Part E: Pegilodecakin 0.8/1 mg + Capecitabine"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with Paclitaxel 80 mg/m2 IV over 3 hours on Days 1, 8, and 15 of every 28-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG014","title":"Part F: Pegilodecakin 0.8/ 1 mg + Paclitaxel"},{"description":"Participants received a 0.8 or 1 mg of Pegilodecakin QD administered SC with Pazopanib 800 mg orally QD.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG015","title":"Part G: Pegilodecakin 0.8/1 mg + Pazopanib"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with Pembrolizumab 2 mg/kg bolus IV infusion over 30 minutes on Day 1 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG016","title":"Part H: Pegilodecakin 0.8/1 mg + Pembrolizumab"},{"description":"Participants received 1.6 or 2 mg of Pegilodecakin QD administered SC with Pembrolizumab 2 mg/kg bolus IV infusion over 30 minutes on Day 1 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG017","title":"Part H: Pegilodecakin 1.6/2 mg + Pembrolizumab"},{"description":"Participants received 3.2 or 4 mg of Pegilodecakin QD administered SC with Pembrolizumab 2 mg/kg bolus IV infusion over 30 minutes on Day 1 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG018","title":"Part H: Pegilodecakin 3.2/4 mg + Pembrolizumab"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with Nivolumab 3 mg/kg IV infusion over 60 minutes on Day 1 of each 14-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG019","title":"Part I: Pegilodecakin 0.8/1 mg + Nivolumab"},{"description":"Participants received 1.6 or 2 mg of Pegilodecakin QD administered SC with Nivolumab 3 mg/kg IV infusion over 60 minutes on Day 1 of each 14-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG020","title":"Part I: Pegilodecakin 1.6/2 mg + Nivolumab"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC with gemcitabine 500 mg/m2 IV over 30 minutes followed by carboplatin targeting an Area Under the Curve of 2 mg/mL x min (AUC2) IV over 60 minutes on Days 1 and 8 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG021","title":"Part J: Pegilodecakin 0.4/0.5 mg + Gemcitabine/Carboplatin"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with gemcitabine 500 mg/m2 IV over 30 minutes followed by carboplatin targeting an AUC2 IV over 60 minutes on Days 1 and 8 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"BG022","title":"Part J: Pegilodecakin 0.8/1 mg + Gemcitabine/Carboplatin"},{"description":"Total of all reporting groups","id":"BG023","title":"Total"}],"measures":[{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"79"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"14"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"16"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"3"},{"groupId":"BG013","value":"4"},{"groupId":"BG014","value":"5"},{"groupId":"BG015","value":"2"},{"groupId":"BG016","value":"4"},{"groupId":"BG017","value":"22"},{"groupId":"BG018","value":"3"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"27"},{"groupId":"BG021","value":"3"},{"groupId":"BG022","value":"5"},{"groupId":"BG023","value":"215"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"38"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"13"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"3"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"4"},{"groupId":"BG016","value":"10"},{"groupId":"BG017","value":"12"},{"groupId":"BG018","value":"2"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"30"},{"groupId":"BG021","value":"2"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"138"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"58"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"14"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"9"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"3"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"3"},{"groupId":"BG015","value":"2"},{"groupId":"BG016","value":"5"},{"groupId":"BG017","value":"16"},{"groupId":"BG018","value":"3"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"23"},{"groupId":"BG021","value":"5"},{"groupId":"BG022","value":"5"},{"groupId":"BG023","value":"166"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"59"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"20"},{"groupId":"BG011","value":"5"},{"groupId":"BG012","value":"3"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"3"},{"groupId":"BG015","value":"4"},{"groupId":"BG016","value":"9"},{"groupId":"BG017","value":"18"},{"groupId":"BG018","value":"2"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"34"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"187"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"4"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"5"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"37"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"98"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"18"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"27"},{"groupId":"BG011","value":"6"},{"groupId":"BG012","value":"6"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"5"},{"groupId":"BG015","value":"6"},{"groupId":"BG016","value":"10"},{"groupId":"BG017","value":"34"},{"groupId":"BG018","value":"5"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"52"},{"groupId":"BG021","value":"5"},{"groupId":"BG022","value":"5"},{"groupId":"BG023","value":"314"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"2"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"4"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"6"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"17"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"1"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"1"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"2"},{"groupId":"BG021","value":"2"},{"groupId":"BG022","value":"1"},{"groupId":"BG023","value":"20"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"93"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"16"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"22"},{"groupId":"BG011","value":"4"},{"groupId":"BG012","value":"6"},{"groupId":"BG013","value":"4"},{"groupId":"BG014","value":"5"},{"groupId":"BG015","value":"6"},{"groupId":"BG016","value":"12"},{"groupId":"BG017","value":"34"},{"groupId":"BG018","value":"4"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"45"},{"groupId":"BG021","value":"3"},{"groupId":"BG022","value":"4"},{"groupId":"BG023","value":"291"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"3"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"22"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"All Participants who received one dose of study intervention(s)."}